Begin main content

Biosimilars — Regulatory, Health Technology Assessment, Reimbursement Trends, and Market Outlook

Published on: January 19, 2018
Project Number: ES0317-000
Product Line: Environmental Scans
Result type: Report

The Environmental Scan identifies and compares information regarding the regulatory frameworks, HTA processes, and reimbursement trends of national and international organizations. It also provides a synopsis of the market outlook for biosimilars and their reference products in Canada.

The findings of this Environmental Scan are based on a literature search and correspondence with key informants from selected Health Technology Assessment organizations and with representatives from Federal, Provincial and Territorial drug plans and cancer agencies in Canada.

Tags

biologics, biosimilar pharmaceuticals, government regulation, pricing, reimbursement mechanisms, technology assessment, therapeutic equivalency, other miscellaneous topics, Biomedical, SEB, biosimilar, follow-on, interchangeability, interchangeable, regulatory, subsequent entry, subsequent entry biologic, subsequent entry biopharmaceutical, subsequent entry biopharmaceuticals, subsequent entry biotherapeutic, subsequent entry biotherapeutics